At least 31 biotechs and pharmas are slated to report earnings this week. The Street anticipates Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and ViroPharma Inc. (NASDAQ:VPHM) to swing to profitability. Arena's top line is expected to increase by 159% to $56.9 million following the launch of its obesity drug Belviq lorcaserin in June. Ligand's revenues, which include royalties on Promacta eltrombopag for idiopathic thrombocytopenia purpura (ITP), are expected to increase by 62% to $9.3 million. ViroPharma markets Cinryze C1 esterase inhibitor for hereditary angioedema (HAE) and is expected to post a 11% increase in revenues to $105.1 million.

Incyte Corp. (NASDAQ:INCY), Luminex Corp. (NASDAQ:LMNX) and Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) are all expected